摘要
目的探讨基质细胞衍生因子-1(SDF-1)与N末端脑钠肽原(NT-proBNP)对围生期心肌病的评估价值。方法选择2012年2月—2017年1月在南阳市第二人民医院产科诊治的围生期心肌病患者60例作为观察组,同期选择在该院进行体检的围生期妇女60例作为对照组,两组都进行SDF-1与NT-proBNP检测,同时进行超声观察与判断。结果观察组的左房内径和室间隔厚度都明显高于对照组,差异有统计学意义(P<0.05);两组右室内径与左心室射血分数对比差异无统计学意义。观察组与对照组的血清NT-proBNP浓度分别为(2.22±0.33)pg/m L和(1.13±0.24)pg/m L,观察组明显高于对照组,差异有统计学意义(P<0.05)。观察组的SDF-1 3’A基因型频率为41.7%(25/60),对照组为20.0%(12/60),观察组明显高于对照组,差异有统计学意义(P<0.05)。logistic回归分析显示NT-proBNP、SDF-1 3’A基因型、左心室射血分数都为导致围生期心肌病发生的主要独立危险因素(P<0.05)。结论 SDF-1与NT-proBNP对围生期心肌病有很好的评估价值,能有效判断疾病状况,也是围生期心肌病发生的独立危险因素。
Objective To investigate the value of SDF-1 and NT-proBNP in the evaluation of peripartum cardiomyopathy. Methods From February 2012 to January 2017, 60 patients of peripartum cardiomyopathyin our hospital diagnosis and treatment were selected as the observation group, 60 women in perinatal period were selected as control group at the same period, The SDF-1 and NT-proBNP in the two groups were detected, and were all given ultrasonic detection and judgment. Results The left atrial diameter and interventricular septal thickness in the observation group were significantly higher than those in the control group（P〈0.05）, and there were no significant difference compared between the two groups of right ventricular diameter and left ventricular ejection fraction. The serum NT-proBNP lelves in the observation group and the control group were（2.22±0.33） pg/m L and（1.13±0.24） pg/m L, respectively, and the observation group were significantly higher than that of the control group（P〈0.05）. The frequency of SDF-1 3, A genotype was 41.7%（25/60） in the observation group, and was 20%（12/60） in the control group, The observation group was also significantly higher than that of the control group（P〈0.05）. Logistic regression analysis showed that NT-proBNP, SDF-1 3, A genotype and left ventricular ejection fraction were the major independent risk factors for peripartum cardiomyopathy（P〈0.05）. Conclusion SDF-1 and NT-proBNP have good evaluation value for peripartum cardiomyopathy, they can effectively judge the disease status, and are also independent risk factors of peripartum cardiomyopathy.
作者
吕树志
周华顶
丁彦春
许德清
LU Shuzhi1, ZHOU Huading1, DING Yanchun2, XU Deqing3(1. Cardiology Department, Nanyang Second General Hospital, Nanyang 473000, China 2. Cardiology Department, The Second Hospital of Dalian Medical University, Dalian 116044, China 3. Obstetrics Department, Nanyang Second General Hospital, Nanyang 473000, Chin)
出处
《药物评价研究》
CAS
2018年第1期114-117,共4页
Drug Evaluation Research
